Citi lowered the firm's price target on Rapid7 to $7 from $11.50 and keeps a Neutral rating on the shares. The firm caught up with the company's investor relations team pre-quiet period, saying it came away incrementally cautious on the Q1/FY26 setup, where fundamental rehabilitation contending with still-crystallizing go-to-market pivots and ambitious plans to capture numerous mandates risks execution being spread thin. This against roughly 50% of the business in persistent annual run-rate declines/churn state, the firm's cautious view on segment AI risk, and scant catalysts ahead leave Citi pessimistic that shares can stage a near-term recovery, the analyst tells investors in a research note.
